Future Directions Beyond Osimertinib in EGFR-Mutant NSCLC

This concluding segment explores the future of EGFR-mutant non-small cell lung cancer (NSCLC) treatment beyond current osimertinib-based therapy. Drs. Mark Socinski and Susan Scott discuss emerging strategies to further personalize care through biomarker-driven treatment selection, novel combination regimens, and therapies designed to overcome acquired resistance. The faculty review the growing role of antibody-drug conjugates (ADCs), bispecific antibodies, VEGF-targeted approaches, and fourth-generation EGFR tyrosine kinase inhibitors aimed at addressing on-target resistance mechanisms. They also highlight the importance of identifying patient subgroups most likely to benefit from specific therapeutic approaches and discuss the ongoing SHEDDER trial, which uses circulating tumor DNA (ctDNA) to guide early treatment intensification. The program concludes by emphasizing the critical role of clinical trial participation in advancing the treatment landscape and supporting more individualized, patient-centered care for patients with EGFR-mutant NSCLC.